MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
MYC/BCL2 Co-Expression Is a Stronger Prognostic Factor Compared With the Cell-of-Origin Classification in Primary CNS DLBCL
Authors
Keywords
-
Journal
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY
Volume 76, Issue 11, Pages 942-948
Publisher
Oxford University Press (OUP)
Online
2017-10-07
DOI
10.1093/jnen/nlx083
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Clinicopathological features of primary diffuse large B-cell lymphoma of the central nervous system - strong EZH2 expression implying diagnostic and therapeutic implication
- (2016) Shuangping Guo et al. APMIS
- MYC and BCL2 overexpression is associated with a higher class of Memorial Sloan-Kettering Cancer Center prognostic model and poor clinical outcome in primary diffuse large B-cell lymphoma of the central nervous system
- (2016) Sehui Kim et al. BMC CANCER
- MYC protein expression is associated with poor prognosis in primary diffuse large B-cell lymphoma of the central nervous system
- (2015) Gustavo Tapia et al. APMIS
- Practical Applications in Immunohistochemistry: Evaluation of Diffuse Large B-Cell Lymphoma and Related Large B-Cell Lymphomas
- (2015) Dennis P. O'Malley et al. ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
- Targetable genetic features of primary testicular and primary central nervous system lymphomas
- (2015) B. Chapuy et al. BLOOD
- Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas
- (2015) Clémentine Sarkozy et al. LANCET ONCOLOGY
- Diffuse large B-cell lymphoma cell-of-origin classification using the Lymph2Cx assay in the context of BCL2 and MYC expression status
- (2015) Samantha Kendrick et al. LEUKEMIA & LYMPHOMA
- MYC and BCL2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with rituximab
- (2014) Anamarija M. Perry et al. BRITISH JOURNAL OF HAEMATOLOGY
- MYC Protein Expression in Primary Diffuse Large B-Cell Lymphoma of the Central Nervous System
- (2014) Kamraan Z. Gill et al. PLoS One
- Frequent triple-hit expression of MYC, BCL2, and BCL6 in primary lymphoma of the central nervous system and absence of a favorable MYClowBCL2low subgroup may underlie the inferior prognosis as compared to systemic diffuse large B cell lymphomas
- (2013) Anna Brunn et al. ACTA NEUROPATHOLOGICA
- MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma
- (2013) H. Horn et al. BLOOD
- Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP
- (2013) Alexandar Tzankov et al. MODERN PATHOLOGY
- The Impact of MYC Rearrangements and “Double Hit” Abnormalities in Diffuse Large B-Cell Lymphoma
- (2013) Pei Lin et al. Current Hematologic Malignancy Reports
- Immunohistochemical Double-Hit Score Is a Strong Predictor of Outcome in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Tina Marie Green et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Expression of MYC and BCL2 in Diffuse Large B-Cell Lymphoma Treated With Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone
- (2012) Nathalie A. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
- (2012) C Visco et al. LEUKEMIA
- Prognostic significance ofMYC,BCL2, andBCL6rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab
- (2011) Nalan Akyurek et al. CANCER
- Immunohistochemical Methods for Predicting Cell of Origin and Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With Rituximab
- (2010) Paul N. Meyer et al. JOURNAL OF CLINICAL ONCOLOGY
- Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival
- (2009) N. A. Johnson et al. BLOOD
- Most primary central nervous system diffuse large B-cell lymphomas occurring in immunocompetent individuals belong to the nongerminal center subtype: a retrospective analysis of 31 cases
- (2009) Eyas M Hattab et al. MODERN PATHOLOGY
- Retracted: Immunohistochemical prognostic markers in diffuse large B-cell lymphoma: validation of tissue microarray as a prerequisite for broad clinical applications (a study from the Lunenburg Lymphoma Biomarker Consortium)
- (2008) D. de Jong et al. JOURNAL OF CLINICAL PATHOLOGY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More